Edward A. Tenthoff

After Phase 3 Novavax Trial Misses Endpoints, Piper Downgrades Despite Remaining Vaccine Efforts

Sarepta's Burn Rate Is Unsustainable, Says Piper Jaffray

Sell Seattle Genetics' Latest Good News: Piper Jaffray

Sarepta's Burn Rate Is Unsustainable, Says Piper Jaffray

Sell Seattle Genetics' Latest Good News: Piper Jaffray

UPDATE: Piper Jaffray Upgrades Vertex Pharmaceuticals Ahead Of Expected Combination Approvals

UPDATE: Piper Jaffray Initiates Coverage on Endocyte on Multiple Drivers at Attractive Valuation

UPDATE: Piper Jaffray Upgrades Vertex Pharmaceuticals Ahead Of Expected Combination Approvals

UPDATE: Piper Jaffray Initiates Coverage on Endocyte on Multiple Drivers at Attractive Valuation

UPDATE: Piper Jaffray Downgrades Sarepta Therapeutics After FDA Reverses View on Eteplirsen NDA Filing

UPDATE: Piper Jaffray Initiates Coverage on Acceleron Pharma on Promising Anemia and Cancer Play

Edward A. Tenthoff Recent News

UPDATE: Piper Jaffray Upgrades Osiris Therapeutics, Pull-Back Offers Attractive Entry Point

UPDATE: Piper Jaffray Raises PT on Regeneron Pharmaceuticals Following Presentation of EYLEA DME Data

UPDATE: Piper Jaffray Downgrades Achillion Pharmaceuticals as Pipeline Setback Pushes Out Approval

UPDATE: Piper Jaffray Downgrades Osiris Therapeutics on DFU Data

UPDATE: Piper Jaffray Initiates XOMA at Overweight on 'Xciting Antibody Play'

UPDATE: Piper Jaffray Initiates OncoMed Pharmaceuticals at Overweight on Emerging Cancer Antibody Play

UPDATE: Piper Jaffray Raises PT on Alnylam Pharmaceuticals Following R&D Day

Piper Jaffray Reiterates Overweight Rating on Novavax on Initiation of Phase I H7N9 Avian Flu Study

UPDATE: Piper Jaffray Upgrades Regeneron Pharmaceuticals to Overweight Following EYLEA Launch

UPDATE: Piper Jaffray Raises PT on Arena Pharmaceuticals on Strong Belviq Survey